Clinical Trials Directory

Trials / Completed

CompletedNCT03314467

Role of Obstructive Sleep Apnea Syndrome in the Occurrence of Diabetic Retinopathy in Type 2 Diabetes.

Status
Completed
Phase
Study type
Observational
Enrollment
60 (actual)
Sponsor
Centre Hospitalier Universitaire Saint Pierre · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Diabetic retinopathy (DR) is the most common visual complication of diabetes. Risk factors for developing DR are diabetes duration, glycemic control, and hypertension . The prevalence ranges from 17 to 61% according to the diabetes duration . Obstructive sleep apnea syndrome (OSAS) is very frequent in Type 2 Diabetes population, reaching a prevalence of 23-48% . Few is known about the exact role of OSAS in the development of DR. A recent study has shown that OSAS is an independent predictor for the progression to pre-/proliferative DR. The purpose of the present study is to assess if the presence of OSA in diabetic patients is a predictive factor for DR occurrence.

Detailed description

Diabetic retinopathy (DR) is the most common visual complication of diabetes. Risk factors for developing DR are diabetes duration, glycemic control, and hypertension. The prevalence ranges from 17 to 61% according to the diabetes duration. Obstructive sleep apnea syndrome (OSAS) is very frequent in Type 2 Diabetes population, reaching a prevalence of 23-48%. Few is known about the exact role of OSAS in the development of DR. A recent study has shown that OSAS is an independent predictor for the progression to pre-/proliferative DR. The purpose of the present study is to assess if the presence of OSA in diabetic patients is a predictive factor for DR occurrence.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTpolysomnography* classical polysomnography * non invasive measurement of blood pressure * blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes

Timeline

Start date
2017-10-06
Primary completion
2021-03-30
Completion
2021-06-30
First posted
2017-10-19
Last updated
2021-09-02

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT03314467. Inclusion in this directory is not an endorsement.